MENSIA Technologies Receives €3.6 Million From The EU To Develop NEWROFEED, A Non-Invasive, Non-Drug Solution For The Treatment Of ADHD In Children

(Attention Deficit Disorder with or without Hyperactivity)

PARIS & RENNES, France--(BUSINESS WIRE)--MENSIA Technologies, a company developing non-invasive medical devices for the care of the Central Nervous System, announced today that it has been awarded €3.6 million from the EU as part of the H2020/SME Instrument call for projects, for its project NEWROFEED. The objective is to develop an original and non-invasive therapeutic medical device for children with ADHD.

Developed in close collaboration with neuroscientists and clinicians, the personalized medical solution NEWROFEED is based on neurofeedback training of the brain. It is used at home under medical supervision to:

• Identify and quantify in real time abnormal brain activity in ADHD patients;
• Personalize treatment with a care protocol adapted to each child;
• Re-train the patients’ brain wave pattern for lasting normalization;
• Monitor daily the child’s observance and progress during the programme.

Providing care in a familiar environment promotes the family’s involvement and hence the child’s willingness to comply with the treatment.

Jean-Yves Quentel, CEO of MENSIA Technologies said, « We are proud that our technology was selected for the EU programme Horizon 2020, one of the most selective programmes funding disruptive technological innovations. We will therefore accelerate the development of our medical device NEWROFEED: to demonstrate its efficacy, we will launch in 2016 a pan-European multicentre clinical study. Our alternative, non-invasive, non-drug treatment satisfies a major need in the etiological treatment of ADHD. »

Neurofeedback is a brain training technique usually applied to the treatment of various disorders (ADHD, addictions, anxiety, etc.), to help regulate the electrical activity in the brain evidenced by electroencephalography (EEG). The technique is based on « serious games » which provide visual or auditory feedback of the brain activity in real time. During these games, the children are rewarded when they manage to alter positively their brain wave pattern, which stimulates their commitment. This physiological treatment induces lasting changes in the brain with positive long-term effects.
(Monastra V.J 2002, Fuchs T 2003, Duric NS 2012, Meisel V 2014).

ADHD, a major public health issue
ADHD is a chronic and incapacitating syndrome, which affects the family, social and school life of young patients, and has major implications on their future adult life. It is characterised by persistent symptoms of inattention, impulsivity and hyperactivity, which may have disabling repercussions on the child’s daily activities. It is one of the most common mental disorders in children, but also one of the most neglected. It is underdiagnosed and poorly managed with drug treatments, not very effective and often associated with adverse effects.
ADHD affects over 5% of children worldwide (Haute Autorité de Santé, December 2014), representing a drug market estimated at $9 billion in 2015.

The technological platform of MENSIA Technologies
The core of the technological innovation is the software suite NeuroRTtm, designed for the development of applications used for real-time monitoring and analysis of brain signals generated by electroencephalography (EEG). Based on the OpenViBE software developed by Inria in close collaboration with experts in neuroinformatics and clinical neurologists, NeuroRTtm is designed to develop applications performing a complete brain analysis cycle, from the acquisition of physiological data to the feedback given to the user. This platform is based on the latest technological breakthroughs in signal processing, applied mathematics, automatic learning and neurosciences. The applications developed with NeuroRT™ are already used in research laboratories to improve our understanding of the human brain, or in a clinical setting, as is the case with the NEWROFEED project.
NeuroRT™ could also provide a non-invasive solution to treat conditions such as depression, post-stroke movement disorders and addictions.

Horizon 2020: https://ec.europa.eu/easme/en/sme/5553/personalized-medical-device-diagnosis-and-treatment-adhd-based-eeg-biomarkers-and

About MENSIA Technologies
Founded in 2012, based in Paris at the international brain and spinal cord research centre ICM and in Rennes, MENSIA Technologies designs and develops non-invasive and non-drug medical devices for the treatment of certain brain disorders.